Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Mar 4, 3:01PM CST

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results GlobeNewswire - Thu Feb 19, 6:30AM CST

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S....

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences GlobeNewswire - Mon Feb 9, 3:01PM CST

BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Feb 4, 3:01PM CST

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy GlobeNewswire - Tue Jan 13, 3:30PM CST

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress GlobeNewswire - Mon Jan 12, 7:00AM CST

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jan 9, 3:01PM CST

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments GlobeNewswire - Thu Jan 8, 3:45PM CST

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering GlobeNewswire - Tue Jan 6, 10:15PM CST

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 298.31 (+0.27%)
Praxis Precision Medicines, Inc. Announces Proposed Public Offering GlobeNewswire - Tue Jan 6, 3:03PM CST

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 298.31 (+0.27%)

Barchart Exclusives

Exxon vs. Chevron: Which Energy Giant Will Pay You for Generations as Oil Prices Surge? Barchart - Fri Mar 20, 6:00PM CDT
Iran tensions and higher oil prices are putting Exxon Mobil and Chevron in focus, but only one looks like the stronger dividend stock today. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.